Compare Humana Inc (HUM) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Vipshop Holdings Ltd - ADR — how do they compare? Humana Inc trades at $400 (market cap $47.81B), while Vipshop Holdings Ltd - ADR trades at $14.63 (market cap $7.01B). The key difference: Humana Inc is far larger — about 6.8× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays the higher dividend (4.25%). Which is the better fit depends on your goals.
| HUM | VIPS | |
|---|---|---|
Market Cap | $47.81B | $7.01B |
Sector | Health | Consumer Cyclical |
52-Week High | $409.42 | $20.68 |
52-Week Low | $163.67 | $12.92 |
Enterprise Value | $56.85B | $3.60B |
Dividend Yield | 0.89% | 4.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
Vipshop (VIPS) trades at $14.56, up 0.41% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 7.07% net income margin and attractive valuation ratios including a P/E of 6.61. Recent Q1 2026 earnings met expectations, and the company is pursuing growth through an outlet store REIT spin-off strategy. Revenue has stabilized around $106 billion after a slight decline from 2023 peaks.
Outlook remains positive given low valuations and analyst consensus, but risks include competitive pressures in Chinese e-commerce and macroeconomic headwinds. The stock offers value opportunity if execution on outlet strategy drives growth, though investors should monitor revenue trends and industry challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
